When its blockbuster cholesterol drug Lipitor loses patent protection this month, Pfizer is hoping that pharmacy benefit managers will not dispense a generic version of the drug to its customers, according to published reports.
Ideas are just as important to a winning company’s overall success as the products and services it sells. So, what’s your company doing to create a culture where the ideas that create your products and services are as important as the products themselves?
The list of participating companies in the 13th Annual Drug Store News Group Industry Issues conference — which will be held Tuesday, Nov. 29, at the highly prestigious New York Athletic Club — reads like a “who’s who” of pharmacy retailing.
A drug commonly prescribed to Type 2 diabetics to improve blood-sugar control also may have a rapid anti-inflammatory effect, according to results from a small study conducted by researchers at the University of Buffalo.
AstraZeneca and Targacept released results of the first of four phase-3 clinical trials that investigated the efficacy and tolerability of a drug that could serve as an adjunct therapy to major depressive disorder patients that had an inadequate response to initial antidepressant therapies.
Biotechnology company Signum Biosciences has entered a collaborative agreement with GlaxoSmithKline whereby GSK will receive the exclusive right to Signum's proprietary phosphatase screening technology.